B. Riley cuts ArriVent Biopharma target price to $29 from $45
AVBP•B. Riley cut its target price for ArriVent Biopharma to $29 from $45.
Related News
Myriad Genetics agrees to sell prenatal testing business to Labcorp for $210 million plus inventory value
MYGN•
EU still committed to keeping oil, coal and gas in ground in Arctic, new strategy says
USO•
Royal Gold repays $250 million in debt
RGLD•
Neurocrine Biosciences initiates Phase 2 study of NBI-'567 in adults with Alzheimer's disease
NBIX•
Planet Labs launches Pelican-12 satellite with updated imaging and communications systems
PL•